Amy Claxton, PhD

  • 3Articles
  • 28.9KReads
  • 2020–2025Active
  • 20Collaborators
  • 37Citations

About

Amy Claxton, PhD, is affiliated with Clinical Development at Bristol Myers Squibb in Princeton, New Jersey. Her publications from 2020 to 2025 focus on schizophrenia and schizoaffective disorders, specifically investigating the safety, tolerability, and efficacy of treatments such as xanomeline with trospium chloride and aripiprazole lauroxil. Her work includes analyses of long-term safety outcomes and clinical trials involving hospitalized patients transitioning to outpatient care. Frequent collaborators include Peter J. Weiden, Yangchun Du, and Andrew J. Cutler.

Publications

JCP
Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials
Original Research

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials

February 26, 2025

In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic...
, , , et al
JCP
Original Research

Long-Term Safety of Aripiprazole Lauroxil

August 18, 2020

Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.
, , , et al
JCP
Original Research

Aripiprazole Lauroxil to Treat Schizophrenia

May 19, 2020

Read a study examining the efficacy and tolerability of the long-acting injectable (LAI) aripiprazole lauroxil from inpatient into follow-up outpatient care.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe